Abstract
Purpose: :
To compare vision-related functioning and health-related quality of life (HRQL) of patients with noninfectious intermediate or posterior uveitis to the US general population and normal-vision reference groups.
Methods: :
Secondary analysis of HRQL data administered at baseline to patients with noninfectious intermediate or posterior uveitis, participating in a 26-week, multicenter, masked, randomized, sham-controlled trial of dexamethasone intravitreal implant (n = 224). PRO measures included the NEI VFQ-25, SF-36®, SF-6D, and EQ-5D. SF-36 and SF-6D scores were compared to US general population samples using the National Health Measurement Study (n = 3844) and Medical Expenditure Panel Survey (n = 955) data. EQ-5D scores were compared to the MEPS data. The VFQ-25 data were compared with published VFQ-25 scores from a normal-vision reference group (n = 122).
Results: :
Uveitis patients had significantly more impaired SF-36 Mental Component Summary scores and SF-6D scores compared to a general US population sample (P < .001). No significant differences were found for the Physical Component Summary scores and EQ-5D scores between the uveitis and general population samples. Based on the VFQ-25, compared with a normal-vision population, the uveitis sample had clinically significant impairments across all VFQ-25 subscales and the composite score, with all subscale score differences exceeding 10 points (P < .001).
Conclusions: :
Compared to the US general population and normal-vision reference groups, noninfectious intermediate or posterior uveitis results in meaningful reductions in mental health outcomes, HRQL, and vision-related functioning.
Clinical Trial: :
http://www.clinicaltrials.gov 00333814
Keywords: uveitis-clinical/animal model • quality of life